Skip to main content
MedPathMedPath Home
Clinical Trials/NCT07402551
NCT07402551
Recruiting
Phase 2

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of RC1416 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Nanjing RegeneCore Biotech Co., Ltd.74 sites in 1 country180 target enrollmentStarted: March 6, 2026Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
InterventionsRC1416RC1416 Placebo

Overview

Phase
Phase 2
Status
Recruiting
Sponsor
Nanjing RegeneCore Biotech Co., Ltd.
Enrollment
180
Locations
74
Primary Endpoint
moderate or severe COPD exacerbations (AECOPD) and forced expiratory volume in 1 Second (FEV1)
OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Overview

Brief Summary

This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of RC1416 injection in patients with moderate to severe chronic obstructive pulmonary disease (COPD).

Detailed Description

Each participant will receive the study treatment once every two weeks for a total treatment duration of 52 weeks. The study aims to evaluate the annualized rate of moderate or severe COPD exacerbations (AECOPD) and the change in FEV1 from baseline over the 52-week treatment period. The changes in FeNO, total IgE, eosinophil count, and TARC levels from baseline will be evaluated.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
40 Years to 85 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Aged 40 to 85 years (inclusive) at the time of signing the informed consent form, regardless of gender.
  • •Body Mass Index (BMI) ≥ 16 kg/m².
  • •Meets the diagnostic criteria for chronic obstructive pulmonary disease (COPD), and has medical records or relevant documentation indicating a history of COPD for ≥ 12 months at screening.
  • •Post-bronchodilator ratio of forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) \< 0.7, and post-bronchodilator FEV1 ≥ 30% and \< 80% of the predicted value at screening.
  • •A current smoker or former smoker with a smoking history of ≥ 10 pack-years, or a history of exposure to other risk factors.
  • •A score of ≥ 2 on the modified Medical Research Council (mMRC) dyspnea scale at screening.
  • •Medical records or relevant documentation showing ≥ 2 moderate COPD. exacerbations (AECOPD) or ≥ 1 severe AECOPD within the 12 months prior to screening.
  • •Medical records or relevant documentation showing receipt of background triple therapy (ICS + LABA + LAMA) for ≥ 3 months prior to randomization.
  • •A blood eosinophil count ≥ 150/mm³ (0.15×10⁹/L) at screening.

Exclusion Criteria

  • •A current diagnosis of asthma or a history of asthma.
  • •Presence of other significant pulmonary diseases except COPD as judged by the Investigator.
  • •History of malignancy .
  • •A history of autoimmune diseases , or treatment with biologics or systemic immunosuppressants for inflammatory diseases within 8 weeks or 5 half-lives (whichever is longer) prior to signing the informed consent form.
  • •Presence of recurrent, chronic, or other active infections at screening.
  • •Currently receiving or planning to start long-term oxygen therapy or mechanical ventilation during the study period.
  • •Diagnosis of α1-antitrypsin deficiency.
  • •Active hepatitis B, active hepatitis C, positive human immunodeficiency virus (HIV) antibody, or positive Treponema pallidum antibody (TP-Ab).
  • •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Arms & Interventions

RC1416 Injection

Experimental

Intervention: RC1416 (Drug)

Placebo Control

Placebo Comparator

Intervention: RC1416 Placebo (Drug)

Outcomes

Primary Outcomes

moderate or severe COPD exacerbations (AECOPD) and forced expiratory volume in 1 Second (FEV1)

Time Frame: During 52 weeks

Evaluate the annualized rate of AECOPD and the change in FEV1 from baseline

Secondary Outcomes

  • The safety and tolerability(During 52 weeks)
  • pharmacokinetic(During 52 weeks)
  • immunogenicity(During 52 weeks)
  • biomarkers predictive of the efficacy(During 52 weeks)

Investigators

Sponsor
Nanjing RegeneCore Biotech Co., Ltd.
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (74)

Loading locations...

Similar Trials

Completed
Not Applicable
A Phase II Study to Evaluate the Safety and Efficacy of SAL003 Combined With Atorvastatin in Hypercholesterolemia and Mixed Dyslipidemia
NCT07278830Shenzhen Salubris Pharmaceuticals Co., Ltd.214
Recruiting
Phase 2
A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)
NCT07280156Protalix150
Recruiting
Phase 2
A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis
NCT07314060Chia Tai Tianqing Pharmaceutical Group Co., Ltd.36
Not yet recruiting
Not Applicable
A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE）
NCT07274137MindRank AI Ltd738
Recruiting
Phase 2
A Study of Picankibart in Patients With Active Psoriatic Arthritis
NCT07295509Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.222